Commercialization Office

Build the U.S. commercialization system before scale makes mistakes expensive.

UEM works with smaller, emerging, and global manufacturers preparing pharmaceutical or biosimilar products for the U.S. market and with companies commercializing aesthetic products through professional practices—especially when the team is lean and the operating model is still taking shape.

Readiness · Organization · Field · Experts

Engagements

Start with the decision need, then define the right scope.

Engagement design depends on launch stage, evidence quality, internal capability, and decision urgency. UEM does not publish artificial fixed packages or promise outcomes before understanding that context.

01

Commercial Readiness Diagnostic

A disciplined view of whether the launch system is ready to support the commercial ambition.

  • Leadership and workstream interviews
  • Evidence, assumption, dependency, and decision review
  • Readiness gaps and critical-path exposure
  • Executive findings with prioritized next decisions

02

Fractional U.S. Commercialization Office

Senior operating leadership for companies that need U.S. commercial discipline before a full internal organization is practical.

  • Commercial model and launch-governance design
  • Cross-functional decision cadence
  • Capability sequencing and partner orchestration
  • Executive and board-ready decision support

03

Organization, Field & Hiring Design

Build the organization around the strategy, timeline, market, and evidence—not around a generic industry template.

  • Organization and role architecture
  • Field-force and manager-span design
  • Recruiting sequence and selection scorecards
  • Onboarding, certification, and launch-readiness planning

04

Scoped Expert Engagements

Bring specialist judgment into a defined decision without pretending one firm should own every capability.

  • Decision-specific expert briefs
  • Structured evidence and recommendation capture
  • Build, buy, rent, or defer analysis
  • Transparent boundaries and conflict disclosure

Adjacent specialization

Medical aesthetics commercialization

UEM applies commercialization discipline to injectables, professional skincare, and other practice-dispensed aesthetic products serving dermatology, plastic-surgery, medical-office, and med-spa channels.

The work connects channel design, practice adoption, field and partner models, evidence, launch governance, and performance measurement without treating aesthetics as a copy of the pharmaceutical market.

Explore aesthetic medicine commercialization

Best fit

Built for a consequential U.S. commercialization decision.

  • An emerging U.S. biopharma or global manufacturer preparing for a first U.S. launch.
  • A launch roughly 6–24 months away with key commercial capabilities still to define.
  • A focused or specialty model where disciplined sequencing matters more than organizational size.
  • An aesthetic product manufacturer or professional-practice group making a consequential channel, portfolio, or growth decision.
  • A leadership team that wants assumptions challenged and decisions documented—not simply endorsed.

Clear boundaries

A decision layer—not another system of record.

UEM and the developing RxLaunchOS product are not intended to replace CRM, data platforms, agency execution, market-access specialists, or the accountable leaders inside the manufacturer.

The role is to connect the evidence and operating choices across those capabilities, identify where specialist expertise is required, and improve the quality and timing of executive decisions.

See how RxLaunchOS extends this model

Define the problem before defining the engagement.

Start a conversation

Rexa is Upper Echelon Management's public AI concierge. Do not share patient information, passwords, trade secrets, or confidential company information.